11-04-2009, SCHOTT North America, Inc.
SCHOTT Pharmaceutical Packaging Inaugurates New Syringe Production Line with Symposium
Congressman Visits to Highlight Expanded Job Opportunities
SCHOTT now offers a complete product portfolio of syringes, vials, and cartridges from its U.S. location. The $14MM expansion of the Lebanon facility will require a significant influx of employees. Current plans call for creating approximately 40 new jobs over the course of the coming year.
US Representative Tim Holden, who was instrumental in securing federal funding for SCHOTT, opened the event with a brief congratulatory address.
“SCHOTT’s continued investment in Lebanon County is to be commended and has provided a welcomed boost to the economic vitality of the area.” Holden said, “I offer my congratulations to SCHOTT on their success in Pennsylvania as well as their many accomplishments throughout the United States and abroad in the global marketplace.”
“The new syringe facility in U.S. is the first SCHOTT syringe production location outside of Europe. This shows our dedication to the American market and our intention to provide security of supply and service to our local customers,” said Ralf Bouffleur, Vice President SCHOTT Pharmaceutical Packaging. “SCHOTT has offered pioneering contributions to the safe protection and storage of drugs for 125 years. Long-term commitment, quality and reliability has made us a dependable partner for the pharmaceutical industry – we will continue to be for the long-term.
After an official ceremonial act, the symposium started with a detailed introduction to the SCHOTT syringe facility and an outlook to planned future developments, followed by an overview of the pharmaceutical market and perspectives, quality by design and container system development as well as regulatory trends and requirements. A highlight of the first day was the plant tour with special focus on the brand new syringes facility.
The second day provided insights into the production of high quality tubing glass and glass containers, highly advanced visual inspection systems, packaging challenges and innovative solutions for protein drugs and different case studies.
“Our symposium sought not only to educate and inform about the current state of the pharmaceutical industry,” said Renard Jackson, SCHOTT Vice President and General Manager of Pharmaceutical Packaging, “but to demonstrate SCHOTT’s commitment to the highest quality products and manufacturing procedures. Our customers got to see firsthand the kind of care and attention to the most minute detail we put into every piece that comes off our lines, whether it is a syringe, vial, or cartridge.”
“The event was highly educational and enjoyable with great networking opportunities” said one attendant. “I was impressed by the high manufacturing quality and technical engineering. Now there is a viable local alternative to the existing syringe supplier in U.S.”
Long-term plans for the Lebanon facility include further investment in excess of $30MM and incremental employment of 80, although the timing of the investment remains uncertain.
SCHOTT products and production processes conform to the U.S. Food and Drug Administration’s current good manufacturing practice (cGMP) standards. The production line incorporates the most advanced techniques, including dimensional camera inspection and clean room final packaging.
SCHOTT is celebrating its 125th year in business, and the 40th anniversary of the opening of its first American operations in Duryea, Pa. The company has been producing pharmaceutical products in the United States since 1992.
|Innovation||Products||Press||Careers||SCHOTT North America|